Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03726333 · ClinicalTrials.gov registry record · Phase 1
Hepatic Impairment Study for Lorlatinib in Cancer Patients
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT03726333: Clinical Trial Phase 1 study, sponsored by Pfizer.
NCT03726333 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03726333, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a phase 1 study in advanced cancer patients with varied hepatic functions to evaluate the potential effect of hepatic impairment on pharmacokinetics and safety of lorlatinib and provide dose recommendation for patients with hepatic impairment if possible.
Primary Outcome
AUC24 was defined as area under the plasma concentration time profile during 1 dosing interval (24 hours).
Interventions
- DRUG lorlatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-01-14 |
| Est. Completion | 2021-07-08 |
| Phase | Phase 1 |
Why NCT03726333 stopped before completion
NCT03726333 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which lorlatinib is the first listed.
NCT03726333 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03726333 about?
NCT03726333 is a clinical study titled "Hepatic Impairment Study for Lorlatinib in Cancer Patients". This is a phase 1 study in advanced cancer patients with varied hepatic functions to evaluate the potential effect of hepatic impairment on pharmacokinetics and safety of lorlatinib and provide dose recommendation for patients with hepatic impairment if possible.
What is the current status of trial NCT03726333?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2020-01-14. Estimated completion is 2021-07-08.
What interventions are being tested in trial NCT03726333?
The interventions under investigation include: lorlatinib (DRUG).
Who is sponsoring clinical trial NCT03726333?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03726333's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI